[go: up one dir, main page]

ATE214097T1 - Die ansteckung blockierende malariaimpfstoffe - Google Patents

Die ansteckung blockierende malariaimpfstoffe

Info

Publication number
ATE214097T1
ATE214097T1 AT92911372T AT92911372T ATE214097T1 AT E214097 T1 ATE214097 T1 AT E214097T1 AT 92911372 T AT92911372 T AT 92911372T AT 92911372 T AT92911372 T AT 92911372T AT E214097 T1 ATE214097 T1 AT E214097T1
Authority
AT
Austria
Prior art keywords
present
vaccines
blocking
infection
transmission
Prior art date
Application number
AT92911372T
Other languages
English (en)
Inventor
David G Kaslow
Philip J Barr
Original Assignee
Us Gov Health & Human Serv
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Chiron Corp filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE214097T1 publication Critical patent/ATE214097T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT92911372T 1991-05-08 1992-05-07 Die ansteckung blockierende malariaimpfstoffe ATE214097T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/697,275 US5217898A (en) 1988-05-02 1991-05-08 Expression of the P. falciparum transmission-blocking antigen in yeast
PCT/US1992/003579 WO1992019758A1 (en) 1991-05-08 1992-05-07 Transmission-blocking vaccine against malaria

Publications (1)

Publication Number Publication Date
ATE214097T1 true ATE214097T1 (de) 2002-03-15

Family

ID=24800510

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92911372T ATE214097T1 (de) 1991-05-08 1992-05-07 Die ansteckung blockierende malariaimpfstoffe

Country Status (6)

Country Link
US (1) US5217898A (de)
EP (1) EP0584201B1 (de)
AT (1) ATE214097T1 (de)
AU (1) AU662151B2 (de)
DE (1) DE69232460T2 (de)
WO (1) WO1992019758A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014486A1 (en) 1991-02-22 1992-09-03 THE UNITED STATES OF AMERICA as represented by THE SECRETARY, THE U.S. DEPARTMENT OF COMMERCE Transmission blocking vaccine against malaria
US6355256B1 (en) 1994-09-30 2002-03-12 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
GB9422827D0 (en) * 1994-11-11 1995-01-04 Imperial College Delivery system
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
AU3439799A (en) * 1998-04-30 1999-11-23 Chiron S.P.A. Immunization against and treatment for infection by (h.pylori)
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
CN102838668A (zh) * 2012-09-13 2012-12-26 兰州生物制品研究所有限责任公司 一种恶性疟原虫pfs25蛋白二聚体衍生物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4735799A (en) * 1987-01-14 1988-04-05 Patarroyo Manuel E Malaria vaccine
DE68926712T2 (de) * 1988-05-02 1997-04-17 The United States Of America, Represented By The Secretary, U.S. Department Of Commerce, Springfield, Va. Gen zum kodieren eines antigens gegen menschlichen malaria impfstoff
WO1992014486A1 (en) * 1991-02-22 1992-09-03 THE UNITED STATES OF AMERICA as represented by THE SECRETARY, THE U.S. DEPARTMENT OF COMMERCE Transmission blocking vaccine against malaria
CA2106464A1 (en) * 1991-03-20 1992-09-21 Enzo Paoletti Malaria recombinant poxvirus vaccine

Also Published As

Publication number Publication date
DE69232460D1 (de) 2002-04-11
AU662151B2 (en) 1995-08-24
AU1913292A (en) 1992-12-21
DE69232460T2 (de) 2002-09-26
US5217898A (en) 1993-06-08
EP0584201A4 (en) 1997-03-19
EP0584201A1 (de) 1994-03-02
EP0584201B1 (de) 2002-03-06
WO1992019758A1 (en) 1992-11-12

Similar Documents

Publication Publication Date Title
FR2744724B1 (fr) Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
CA2123612A1 (en) Hybrid protein between cs from plasmodium and h bsag
EP1964573A3 (de) Verfahren zur Induzierung und/oder Verbesserung einer Immunreaktion auf Tumorantigene
HUT37460A (en) Cloning dna for malaria antigens
PT82975B (pt) Processo de preparacao do antigenio peptidico imunogenico correspondente a proteina circunsporozoito do plasmodium vivax e de vacina contra a malaria
ATE214097T1 (de) Die ansteckung blockierende malariaimpfstoffe
WO1995026982A3 (en) Malaria peptides
ATE78041T1 (de) Beschirmendes peptidantigen uebereinstimmend mit plasmodium-falciparum-circumsporozoitprotein.
ZA851305B (en) Dna sequences,recombinant dna molecules and processes for producing late schizont-merozoite stage specific antigens of the human malarial parasite plasmodium falciparum
IL90849A0 (en) Synthetic vaccine against p.falciparum malaria
IL90134A0 (en) Gene for encoding a human malaria vaccine antigen,malarial vaccines and pharmaceutical compositions
ATE157881T1 (de) Impfstoff zur immunisierung von katzen gegen toxoplasmen ohne verbreitung der oozysten
DK0638316T3 (da) Rekombinante adenovirusvacciner
CA2102624A1 (en) Transmission-blocking vaccine against malaria
BR9604989A (pt) Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção
GR3029665T3 (en) 16 kDa SURFACE PROTEIN OF -i(P. FALCIPARUM).
DE3851310D1 (de) Synthetische Peptide, die immunologische Aktivität zeigen, benutzbar, um eine Impfung gegen Malaria vorzubereiten.
SE8702698L (sv) Polypeptid, anvendbar for framstellning av antimalariavacciner och diagnostest for pavisande av malariasjukdomar
MX9200711A (es) Un antigeno de fases sanguineas de plasmodium falciparum su preparacion y utilizacion.
ATE144537T1 (de) Merozoit-oberflächen-plasmodium-falciparum- antigen
TH3773A (th) วัคซีนป้องกันมาเลเรีย